APPENDIX CANCER/PSEUDOMYXOMA PERITONEI RESEARCH FOUNDATION, INC. (OR ACPMP)

FINANCIAL STATEMENTS

Year Ended December 31, 2025

Maillie®
ACCOUNTANTS · ADVISORS

APPENDIX CANCER/PSEUDOMYXOMA PERITONEI RESEARCH FOUNDATION, INC. (OR ACPMP)

TABLE OF CONTENTS

YEAR ENDED DECEMBER 31, 2025

	Page
Independent Accountants' Review Report	1
Financial Statements	
Statement of Assets, Liabilities and Net Assets -- Modified Cash Basis	2
Statement of Support, Revenue and Expenses -- Modified Cash Basis	3
Statement of Functional Expenses -- Modified Cash Basis	4
Notes to the Financial Statements	5

Maillie LLP | maillie.com
500 North Lewis Road, Limerick PA 19468
600 Willowbrook Lane, Suite 624, West Chester, PA 19382
PO Box 11847, Wilmington, DE 19850-1847

Independent Accountants' Review Report

To the Board of Directors of
Appendix Cancer/Pseudomyxoma Peritonei Research Foundation, Inc. (or ACPMP)
Springfield, Pennsylvania

We have reviewed the accompanying financial statements of Appendix Cancer/Pseudomyxoma Peritonei Research Foundation, Inc. (or ACPMP) (a nonprofit organization), which compromise the statement of assets, liabilities and net assets -- modified cash basis as of December 31, 2025, and the related statements of support, revenue and expenses -- modified cash basis and statement of functional expenses -- modified cash basis for the year then ended, and the related notes to the financial statements. A review includes primarily applying analytical procedures to management's financial data and making inquiries of the Organization's management. A review is substantially less in scope than an audit, the objective of which is the expression of an opinion regarding the financial statements as a whole. Accordingly, we do not express such an opinion.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with the modified cash basis of accounting; this includes determining that the modified cash basis of accounting the Organization uses is an acceptable basis for the preparation of financial statements in the circumstances. Management is also responsible for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement whether due to fraud or error.

Accountants' Responsibility

Our responsibility is to conduct the review engagement in accordance with Statements on Standards for Accounting and Review Services promulgated by the Accounting and Review Services Committee of the AICPA. Those standards require us to perform procedures to obtain limited assurance as a basis for reporting whether we are aware of any material modifications that should be made to the financial statements for them to be in accordance with the modified cash basis of accounting. We believe that the results of our procedures provide a reasonable basis for our conclusion.

We are required to be independent of Appendix Cancer/Pseudomyxoma Peritonei Research Foundation, Inc. (or ACPMP) and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements related to our review.

Accountants' Conclusion

Based on our review, we are not aware of any material modifications that should be made to the accompanying financial statements in order for them to be in conformity with the modified cash basis of accounting.

Basis of Accounting

We draw attention to Note A of the financial statements, which describes the basis of accounting. The financial statements are prepared in accordance with the modified cash basis of accounting, which is a basis of accounting other than accounting principles generally accepted in the United States of America. Our conclusion is not modified with respect to this matter.

Maillie LLP

Limerick, Pennsylvania
June 4, 2026

Appendix Cancer/Pseudomyxoma Peritonei Research Foundation, Inc. (OR ACPMP)

STATEMENT OF ASSETS, LIABILITIES AND NET ASSETS -- MODIFIED CASH BASIS

DECEMBER 31, 2025

ASSETS		
Cash and cash equivalents	$	333,499
Investments		1,912,360
TOTAL ASSETS	$	2,245,859
NET ASSETS		
Without donor restrictions	$	2,245,859

See accompanying notes and independent accountants' review report.

Appendix Cancer/Pseudomyxoma Peritonei Research Foundation, Inc. (OR ACPMP)

STATEMENT OF SUPPORT, REVENUE AND EXPENSES -- MODIFIED CASH BASIS

YEAR ENDED DECEMBER 31, 2025

	Without Donor Restriction	With Donor Restriction	Totals
Revenue and Support			
Contributions			
Events	$ 346,013	$ -	$ 346,013
Other	378,360	-	378,360
Investment income	82,008	-	82,008
Merchandise sales	3,002	-	3,002
TOTAL REVENUE AND SUPPORT	809,383	-	809,383
Expenses			
Program Services			
Grants	360,657	-	360,657
Education	238,795	-	238,795
Support Services			
Management and general	82,615	-	82,615
Fundraising	99,484	-	99,484
TOTAL EXPENSES	781,551	-	781,551
CHANGE IN NET ASSETS	27,832	-	27,832
NET ASSETS AT BEGINNING OF YEAR	2,218,027	-	2,218,027
NET ASSETS AT END OF YEAR	$ 2,245,859	$ -	$ 2,245,859

See accompanying notes and independent accountants' review report.

Appendix Cancer/Pseudomyxoma Peritonei Research Foundation, Inc. (OR ACPMP)

STATEMENT OF FUNCTIONAL EXPENSES -- MODIFIED CASH BASIS

YEAR ENDED DECEMBER 31, 2025

	Program Services			Support Services		
	Grants and Contributions	Education	Total Program Services	Management and General	Fund-Raising	Totals
FUNCTIONAL EXPENSES						
Advertising and marketing	$ -	$ 70,556	$ 70,556	$ 12,059	$ 8,037	$ 90,652
Salary and wages	-	63,415	63,415	26,768	48,628	138,811
Payroll taxes and processing	-	6,768	6,768	2,857	5,190	14,815
Conference registrations and fees	-	1,204	1,204	-	-	1,204
Educational sessions and exhibits	-	58,829	58,829	-	-	58,829
Fees and licenses	-	-	-	1,577	-	1,577
Bank fees and service charges	-	-	-	4,798	4,747	9,545
Dues and subscriptions	-	2,939	2,939	21,854	5,216	30,009
Event cost	-	-	-	-	4,323	4,323
Insurance	-	-	-	4,961	-	4,961
Website	6,373	6,373	12,746	-	6,374	19,120
Office and miscellaneous	-	-	-	81	-	81
Grant administration	19,284	-	19,284	-	-	19,284
Scholarships	-	10,000	10,000	-	-	10,000
Sponsorships	-	15,500	15,500	-	-	15,500
Merchandise giveaways	-	-	-	-	123	123
Postage and delivery	-	-	-	794	3,970	4,764
Professional fees	-	2,288	2,288	6,866	12,876	22,030
Research grants	335,000	-	335,000	-	-	335,000
Meals and catering	-	185	185	-	-	185
Travel	-	738	738	-	-	738
TOTAL FUNCTIONAL EXPENSES	$ 360,657	$ 238,795	$ 599,452	$ 82,615	$ 99,484	$ 781,551

See accompanying notes and independent accountants' review report.

NOTE A - NATURE OF BUSINESS AND SIGNIFICANT ACCOUNTING POLICIES

Nature of Business

Appendix Cancer/Pseudomyxoma Peritonei Research Foundation, Inc. (or ACPMP) (the "Foundation") was established in 2008 to fund and support promising research to find a cure for Pseudomyxoma Peritonei (PMP), Appendix Cancer and related Peritoneal Surface Malignancies (PSM) and to fund educational programs for physicians and their patients about these diseases. The Foundation also supports the appendix cancer, PMP and PSM community as a resource for information about managing the disease. The Foundation is supported through donations and proceeds of fundraising events, such as walks. The Foundation may also sell promotional merchandise.

Basis of Accounting

The accompanying financial statements have been prepared on the modified cash basis of accounting which is a comprehensive basis of accounting other than accounting principles generally accepted in the United States of America. That basis differs from generally accepted accounting principles in that revenue and support are recognized when received rather than when earned, and expenses are recognized when paid rather than when the obligation is incurred. Accounts receivable, accounts payable, and other accrued expenses are not reported in these financial statements. However, the Foundation records investments at their fair market value rather than cost.

Under generally accepted accounting principles, the contribution of services is recognized if the services received (a) create or enhance nonfinancial assets or (b) require specialized skills that are provided by individuals possessing those skills and would typically need to be purchased if not provided by donation. Certain contributed goods and services which may require recognition under generally accepted accounting principles are not recorded in these modified cash basis statements.

Financial Statement Presentation

The financial statements of the Foundation have been prepared in accordance with the modified cash basis of accounting, which require the Foundation to report information regarding its financial position and activities according to the following net asset classifications:

Net assets without donor restrictions: Net assets that are not subject to donor-imposed restrictions and may be expended for any purpose in performing the primary objectives of the Foundation. These net assets may be used at the discretion of the Foundation's management and the board of directors.

NOTE A - NATURE OF BUSINESS AND SIGNIFICANT ACCOUNTING POLICIES (Continued)

Net assets with donor restrictions: Net assets subject to stipulations imposed by donors, and grantors. Some donor restrictions are temporary in nature; those restrictions will be met by actions of the Foundation or by the passage of time. Other donor restrictions are perpetual in nature, whereby the donor has stipulated the funds be maintained in perpetuity. When a restriction expires, net assets with donor restrictions are reclassified to net assets without donor restrictions. Support that is restricted by the donor is reported as an increase in net assets without donor restrictions if the restriction expires in the same reporting period in which the support is received and fully spent.

Use of Estimates

The preparation of financial statements on the modified cash basis of accounting requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from these estimates.

Contributions

Contributions are recorded when received. The Foundation on occasion will receive contributions where the donor has restricted use of funds for a particular purpose. There were no donor restricted contributions or grants received in the year ending December 31, 2025.

The Foundation receives services from a number of volunteers who give significant amounts of their time to the Foundation's programs, fundraising, and management. No amounts have been reflected for these types of donated services. In addition significant accounting and administrative services are provided pro-bono, but amounts have not been quantified.

Revenue Recognition

The Foundation also offered promotional merchandise for sale on-line. Revenue from merchandise sales is recorded when received.

Cash and Cash Equivalents

The Foundation considers all highly liquid investments available for current use with an initial maturity of three months or less to be cash equivalents. At December 31, 2025 cash is comprised of demand deposits, including a money market account and cash held in an investment account. The Foundation's cash does not exceed FDIC insured limits as of December 31, 2025.

NOTE A - NATURE OF BUSINESS AND SIGNIFICANT ACCOUNTING POLICIES (Continued)

Investments

Investments consist of a brokerage account investing in brokerage certificates of deposit. The investments are reported at fair value in the statement of assets, liabilities and net assets - modified cash basis. Unrealized gain and losses are included in the change in net assets.

Advertising Cost

Costs incurred for advertising included certain promotional materials and related costs and are expensed when incurred.

Allocation of Functional Expenses

The costs of providing the Foundation's programs and other activities have been summarized on a functional basis. Specific expenses that are readily identifiable to a specific program or activity are charged directly to that function. Certain costs have been allocated among the programs and supporting services benefited. These expenses require allocation on a basis that is consistently applied. The expenses that are allocated include compensation and related payroll taxes and benefits which are allocated based on estimates of time and effort taking into consideration job description and responsibilities. Website costs are allocated equally to the functions supported.

Income Taxes

The Foundation is a not-for-profit organization that is exempt from income taxes under Section 501(c)(3) of the Internal Revenue Code and classified by the Internal Revenue Service as other than a private foundation, and as such, contributions to the Foundation qualify for deduction as charitable contributions. However, income generated from activities unrelated to the Foundation's exempt purpose is subject to tax under Section 511 of the Code.

There were no uncertain tax positions recorded in the financial statements at December 31, 2025. The Foundation's tax returns are subject to examination by taxing authorities for up to three years after the returns are filed. During 2024 the Foundation changed its domiciled state from Ohio to Pennsylvania as that is its base of operations. The Foundation registers in various states including its domiciled state (Pennsylvania) and potentially others based on Board evaluation of events and solicitation.

NOTE B - INVESTMENTS AND FAIR VALUE MEASUREMENTS

Professional accounting standards establish a framework for measuring fair value. The framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels.

Level 1 inputs are unadjusted quoted prices for identical assets or liabilities in active markets that the Foundation has the ability to access. Level 2 inputs are other than quoted prices that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on the assumptions used to measure assets and liabilities at fair value. The asset or liability's fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The Foundation's investments in brokerage certificates of deposits are Level 2 investments.

	Amortized Cost	Gross Unrealized Gains	Gross Unrealized Losses	Fair Value
Certificate of Deposit	$ 1,905,690	$ 7,057	$ (387)	$ 1,912,360

Investment income consists of the following:

From Investments	
Interest	$ 82,319
Unrealized gains	(3,377)
	78,942
From Cash Deposits	
Interest	3,066
	$ 82,008

NOTE C - GRANTS, SCHOLARSHIP AND SPONSORSHIP

Research Grants

The Foundation previously awarded research grants through the National Organization for Rare Disorders (NORD), and subsequent administration/distribution was also monitored by NORD.

In 2022, the Foundation established a Scientific Advisory Board (SAB) and implemented an internal process to review applications, award grants and monitor progress.

During 2025, the Foundation awarded grants totaling $275,000. This included a $150,000 Changemaker Grant, $100,000 Clinical Investigator Award in conjunction with the Society for Surgical Oncology, and a $25,000 Young Investigator Award.

Cash outlay for grants was $335,000 for the year ended December 31, 2025. This included $50,000 towards 2023 awards, $50,000 towards 2024 awards, $125,000 towards 2025 awards, $100,000 paid to NORD to fund two Catalyst Research Grants in collaboration with NORD as administrator, and $10,000 towards imaging grants.

As of December 31, 2025, the Foundation has the following grant commitments remaining to be funded:

2022 Awards	$ 25,000
2024 Awards	25,000
2025 Awards	150,000
	$ 200,000

Scholarships

For 2025, scholarships included travel awards totaling $10,000. The travel awards enable physicians or other medical professionals to attend the symposium to increase their knowledge about these diseases.

Sponsorship

The Foundation is a sponsor for various conferences including the Advanced Cancer Therapies Symposium put on by the Society of Surgical Oncology as well as and American Association of Nurse Practitioners conference. Sponsorship includes amounts contributed to the cost of the event and exhibits. Sponsorship totaled $15,500 in the year ended December 31, 2025.

NOTE D - RELATED PARTY TRANSACTIONS

Board

The Foundation is primarily a volunteer organization. The members of the Board of Directors perform administration, management and fundraising activities for the Foundation. Board members have directly paid expenses on behalf of the Foundation. Board members do not seek reimbursement in these circumstances. Board members and their relatives may make contributions to the Foundation as well.

Grants

The Foundation has established a protocol for the SAB to avoid conflicts of interest in the grant review process. Current SAB members are not eligible for an ACPMP grant during their tenure. Given the relatively small population of experts dealing with this rare cancer, ACPMP permits a researcher at the same institution as an SAB reviewer to apply for a grant but requires the SAB member of that institution to recuse him or herself from review of that proposal and, instead, calls upon an unaffiliated ad hoc member with relevant expertise for the reviewer subject matter needed for that proposal.

Certain advisory board members have been awarded grants prior to their tenure. Two of the current Scientific Advisory Board members were awarded a two-year $50,000 research grant (one prior to joining the SAB). The SAB members do not participate in the process that awarded the grants, however, tenure on the SAB can overlap the research and actual funding - progress will is independently evaluated. At December 31, 2025, $25,000 is still committed to be funded on these grants.

NOTE E - CONCENTRATIONS

A substantial amount of the Foundation's revenue is generated from fundraising events. Various different fundraising events are held around the country and Canada. In 2025, one event accounted for approximately 56% of event revenue.

NOTE F – BOARD-DESIGNATED NET ASSETS

As of December 31, 2025, the Foundation has designated net assets totaling $200,000 for grant commitments remaining to funded.

NOTE G - LIQUIDITY AND AVAILABILITY OF FINANCIAL ASSETS

The Foundation has established an investment policy, investing funds in excess of those needed to meet annual expenditures.

The following reflects the Foundation's financial assets as the statement of financial position date, reduced by amounts not available for general use because of contractual or donor-imposed restrictions.

Financial assets at year-end		
Cash and cash equivalents	$	333,499
Investments		1,912,360
		2,245,859
Less:		
Amounts not available for general use		
Board-designated for grants awarded		200,000
	$	2,045,859

NOTE H - SUBSEQUENT EVENTS

The Foundation has evaluated subsequent events through June 4, 2026,the date which the financial statements were available to be issued.

As of the date of this report, the Foundation has committed to three 2026 awards which include a $100,000 Clinical Investigator Award in conjunction with the Society for Surgical Oncology, a $25,000 Young Investigator Award in conjunction with the Society for Surgical Oncology, and a $150,000 Changemaker Research Grant.